Publication | Open Access
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
1.7K
Citations
40
References
2020
Year
In patients with stage IB to IIIA <i>EGFR</i> mutation-positive NSCLC, disease-free survival was significantly longer among those who received osimertinib than among those who received placebo. (Funded by AstraZeneca; ADAURA ClinicalTrials.gov number, NCT02511106.).
| Year | Citations | |
|---|---|---|
Page 1
Page 1